Gary Pace Acquires 30,000 Shares of Cardiff Oncology (NASDAQ:CRDF) Stock

Cardiff Oncology, Inc. (NASDAQ:CRDF) Director Gary Pace acquired 30,000 shares of the business’s stock in a transaction dated Thursday, June 18th. The shares were bought at an average price of $1.22 per share, for a total transaction of $36,600.00. Following the completion of the acquisition, the director owned 1,356,376 shares in the company, valued at approximately $1,654,778.72. This trade represents a 2.26% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Cardiff Oncology Price Performance

Shares of CRDF opened at $1.21 on Monday. The company’s fifty day moving average is $1.63 and its two-hundred day moving average is $1.97. Cardiff Oncology, Inc. has a fifty-two week low of $1.16 and a fifty-two week high of $4.55. The firm has a market cap of $82.73 million, a PE ratio of -1.81 and a beta of 1.36.

Cardiff Oncology (NASDAQ:CRDF) last released its quarterly earnings data on Thursday, May 14th. The company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.05). Cardiff Oncology had a negative return on equity of 95.51% and a negative net margin of 8,527.43%.The firm had revenue of $0.04 million during the quarter, compared to analysts’ expectations of $0.09 million. As a group, equities research analysts anticipate that Cardiff Oncology, Inc. will post -0.66 earnings per share for the current year.

Hedge Funds Weigh In On Cardiff Oncology

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Laurion Capital Management LP raised its holdings in Cardiff Oncology by 7.3% in the 4th quarter. Laurion Capital Management LP now owns 2,646,738 shares of the company’s stock worth $7,437,000 after acquiring an additional 180,866 shares during the period. Acorn Capital Advisors LLC increased its position in shares of Cardiff Oncology by 39.3% during the third quarter. Acorn Capital Advisors LLC now owns 1,962,084 shares of the company’s stock valued at $4,042,000 after purchasing an additional 553,317 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Cardiff Oncology by 7.5% during the 2nd quarter. Geode Capital Management LLC now owns 1,498,838 shares of the company’s stock worth $4,723,000 after acquiring an additional 104,409 shares during the period. Franklin Resources Inc. bought a new position in shares of Cardiff Oncology during the 4th quarter worth approximately $3,388,000. Finally, State Street Corp raised its stake in Cardiff Oncology by 4.0% during the fourth quarter. State Street Corp now owns 1,191,647 shares of the company’s stock worth $3,349,000 after acquiring an additional 45,288 shares in the last quarter. Institutional investors and hedge funds own 16.29% of the company’s stock.

Analyst Ratings Changes

CRDF has been the subject of several recent analyst reports. HC Wainwright downgraded Cardiff Oncology from a “buy” rating to a “neutral” rating in a research note on Monday, June 1st. TD Cowen downgraded shares of Cardiff Oncology from a “buy” rating to a “hold” rating in a research report on Monday, June 1st. Weiss Ratings reissued a “sell (d-)” rating on shares of Cardiff Oncology in a report on Monday, May 18th. Craig Hallum lowered Cardiff Oncology from a “buy” rating to a “hold” rating and set a $2.00 target price on the stock. in a report on Wednesday, June 3rd. Finally, Piper Sandler cut their price objective on Cardiff Oncology from $10.00 to $6.00 and set an “overweight” rating on the stock in a report on Wednesday, February 25th. Three research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Cardiff Oncology currently has an average rating of “Hold” and a consensus target price of $8.75.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. The company is dedicated to the discovery, development and commercialization of novel small-molecule therapies designed to modulate the tumor microenvironment and enhance antitumor immune responses. By focusing on unique immuno-oncology targets, Cardiff seeks to address resistance pathways that limit the effectiveness of existing cancer treatments.

Cardiff’s pipeline comprises several small-molecule immunomodulators in various stages of preclinical and clinical development.